

Kaseta Michael
 Form 3
 December 04, 2017

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Â Kaseta Michael
 (Last) (First) (Middle)

2. Date of Event Requiring Statement
 (Month/Day/Year)
 11/30/2017

3. Issuer Name and Ticker or Trading Symbol
 Aralez Pharmaceuticals Inc. [ARLZ]

4. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

5. If Amendment, Date Original Filed(Month/Day/Year)

C/O ARALEZ
 PHARMACEUTICALS
 INC.,Â 7100 WEST CREDIT
 AVENUE, SUITE 101
 (Street)

Director 10% Owner
 Officer Other
 (give title below) (specify below)
 Interim CFO

MISSISSAUGA,Â A6Â L5N
 OE4
 (City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|------------------------------------|--|---|--|
| Common Shares, without par value | 2,500 ⁽¹⁾ | D | Â |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security | 4. Conversion or Exercise | 5. Ownership Form of | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---|---|--|---------------------------|----------------------|--|
|---|---|--|---------------------------|----------------------|--|

Edgar Filing: Kaseta Michael - Form 3

| | Date Exercisable | Expiration Date | (Instr. 4) Title | Amount or Number of Shares | Price of Derivative Security | Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | |
|-----------------------------|------------------|-----------------|---------------------|----------------------------|------------------------------|--|---|
| Stock Option (Right to Buy) | Â (2) | 11/11/2026 | Common Stock | 37,500 | \$ 4.9 | D | Â |
| Stock Option (Right to Buy) | Â (3) | 03/15/2027 | Common Stock | 5,000 | \$ 2.37 | D | Â |
| Stock Option (Right to Buy) | Â (4) | 05/11/2027 | Common Stock | 25,000 | \$ 1.56 | D | Â |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|---------------|-------|
| | Director | 10% Owner | Officer | Other |
| Kaseta Michael C/O ARALEZ PHARMACEUTICALS INC. 7100 WEST CREDIT AVENUE, SUITE 101 MISSISSAUGA,Â A6Â L5N 0E4 | Â | Â | Â Interim CFO | Â |

Signatures

/s/ Michael
Kaseta

12/04/2017

__Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- Consists of 2,500 Restricted Stock Units granted pursuant to the Aralez Pharmaceuticals Inc. 2016 Amended and Restated Long-Term Incentive Plan, which vest in substantially equal annual installments over the three years immediately following the date of grant (March 15, 2017), subject to continued employment or service to the Company.
- (1) The option vests in substantially equal monthly installments over the three years immediately following the date of grant (March 15, 2017), subject to continued employment or service to the Company.
 - (2) The option vests in substantially equal monthly installments over four years from date of grant (November 11, 2016), subject to continued employment or service to the Company.
 - (3) The option vests in substantially equal monthly installments over four years from date of grant (March 15, 2017), subject to continued employment or service to the Company.
 - (4) The option vests as to 25% of the shares on May 11, 2018, and the remainder vests in substantially equal monthly installments over the 36 months immediately following such date, subject to continued employment or service to the Company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.